<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37310437</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-160X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Rheumatology international</Title><ISOAbbreviation>Rheumatol Int</ISOAbbreviation></Journal><ArticleTitle>Assessment of cutaneous disease activity in early lupus and its correlation with quality of life: a cross-sectional study.</ArticleTitle><Pagination><StartPage>1835</StartPage><EndPage>1840</EndPage><MedlinePgn>1835-1840</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-023-05353-y</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is a multi-system autoimmune disease with varied dermatological manifestations that are almost universal. Overall, lupus disease has a major effect on the quality of life in these patients. We assessed the extent of cutaneous disease in early lupus and correlated it with the SLE quality-of-life (SLEQoL) index and disease activity measures. Patients diagnosed as SLE with the skin involved were recruited at the first presentation and were assessed for cutaneous and systemic disease activity using the cutaneous lupus erythematosus disease area and severity index (CLASI) and the Mexican-SLE disease activity index (Mex-SLEDAI), respectively. Quality of life was assessed with the SLEQoL tool while systemic damage was captured by the SLICC damage index. Fifty-two patients with SLE who had cutaneous involvement were enrolled (40, 76.9% females) with a median disease duration of 1&#xa0;month (1-3.7). The median age was 27.5&#xa0;years (IQR: 20-41). Median Mex-SLEDAI and SLICC damage index were 8(IQR: 4.5-11) and 0 (0-1), respectively. The median CLASI activity and damage scores were 3 (1-5) and 1 (0-1), respectively. Overall, there was no correlation between SLEQoL with CLASI or CLASI damage. Only the self-image domain of SLEQoL correlated with total CLASI (&#x3c1;&#x2009;=&#x2009;0.32; p&#x2009;=&#x2009;0.01) and CLASI-D (&#x3c1;&#x2009;=&#x2009;0.35; p&#x2009;=&#x2009;0.02). There was a weak correlation of CLASI with the Mexican-SLEDAI score (&#x3c1;&#x2009;=&#x2009;0.30; p&#x2009;=&#x2009;0.03) but not with the SLICC damage index. In this cohort of early lupus, cutaneous disease activity in lupus had a weak correlation with systemic disease. Cutaneous features did not appear to influence the quality of life except in the self-image domain.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hinduja</LastName><ForeName>Naga</ForeName><Initials>N</Initials><Identifier Source="ORCID">0009-0003-0767-3208</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mv</LastName><ForeName>Prakashini</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1278-6042</Identifier><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, 751024, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padhee</LastName><ForeName>Sourav</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0003-9683-7808</Identifier><AffiliationInfo><Affiliation>Department of Research and Development, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maikap</LastName><ForeName>Debashis</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8093-8303</Identifier><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, 751024, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Padhan</LastName><ForeName>Prasanta</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-2545-9032</Identifier><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, 751024, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kar</LastName><ForeName>Hemanta Kumar</ForeName><Initials>HK</Initials><Identifier Source="ORCID">0000-0003-1828-8949</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Misra</LastName><ForeName>Ramnath</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-7921-4199</Identifier><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, 751024, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Srinivas</LastName><ForeName>C R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Sakir</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4631-311X</Identifier><AffiliationInfo><Affiliation>Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, KIIT University, Bhubaneswar, 751024, India. sakir005@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rheumatol Int</MedlineTA><NlmUniqueID>8206885</NlmUniqueID><ISSNLinking>0172-8172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008178" MajorTopicYN="Y">Lupus Erythematosus, Cutaneous</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CLASI</Keyword><Keyword MajorTopicYN="N">Cutaneous lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Lupus</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">SLE</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>13</Day><Hour>13</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>13</Day><Hour>11</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37310437</ArticleId><ArticleId IdType="doi">10.1007/s00296-023-05353-y</ArticleId><ArticleId IdType="pii">10.1007/s00296-023-05353-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Yell JA, Mbuagbaw J, Burge SM (1996) Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 135(3):355&#x2013;362</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2133.1996.d01-1004.x</ArticleId><ArticleId IdType="pubmed">8949425</ArticleId></ArticleIdList></Reference><Reference><Citation>Stull C, Sprow G, Werth VP (2023) Cutaneous Involvement in Systemic Lupus Erythematosus: A Review for the Rheumatologist. J Rheumatol 50(1):27&#x2013;35</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.220089</ArticleId><ArticleId IdType="pubmed">36109075</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A, Landmann A (2014) The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun 48&#x2013;49:14&#x2013;19</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2014.01.021</ArticleId><ArticleId IdType="pubmed">24486120</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilliam JN, Sontheimer RD (1981) Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 4(4):471&#x2013;475</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0190-9622(81)80261-7</ArticleId><ArticleId IdType="pubmed">7229150</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, Kantor J, Kim E, Militello G, McGinnis K, Richardson S, Treat J, Vittorio C, Van Voorhees A, Werth VP (2005) The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 125(5):889&#x2013;94. https://doi.org/10.1111/j.0022-202X.2005.23889.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0022-202X.2005.23889.x</ArticleId><ArticleId IdType="pubmed">16297185</ArticleId><ArticleId IdType="pmc">3928016</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn A, Amler S, Beissert S, B&#xf6;hm M, Brehler R, Ehrchen J et al (2010) Revised cutaneous lupus erythematosus disease area and severity index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus: revised CLASI for cutaneous lupus erythematosus. Br J Dermatol 163(1):83&#x2013;92</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2010.09799.x</ArticleId><ArticleId IdType="pubmed">20394621</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein RS, Morganroth PA, Werth VP (2010) Cutaneous Lupus and the CLASI Instrument. Rheum Dis Clin North Am. 36(1):33&#x2013;51</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2009.12.001</ArticleId><ArticleId IdType="pubmed">20202590</ArticleId><ArticleId IdType="pmc">3035848</ArticleId></ArticleIdList></Reference><Reference><Citation>Leong KP, Kong KO, Thong BYH, Koh ET, Lian TY, Teh CL et al (2005) Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology 44(10):1267&#x2013;76</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keh605</ArticleId><ArticleId IdType="pubmed">15797980</ArticleId></ArticleIdList></Reference><Reference><Citation>Aziz MM, Galal MAA, Elzohri MH, El-Nouby F, Leong KP (2018) Cross-cultural adaptation and validation of Systemic Lupus Erythematosus Quality of Life questionnaire into Arabic. Lupus 27(5):780&#x2013;787</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317747714</ArticleId><ArticleId IdType="pubmed">29308728</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang HZ, Lin ZG, Li HJ, Du Q, Tian W, Wang SY et al (2018) The Chinese version of the SLEQOL is a reliable assessment of health-related quality of life in Han Chinese patients with systemic lupus erythematosus. Clin Rheumatol 37(1):151&#x2013;60</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-017-3910-4</ArticleId><ArticleId IdType="pubmed">29168029</ArticleId></ArticleIdList></Reference><Reference><Citation>Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210&#x2013;216</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2230.1994.tb01167.x</ArticleId><ArticleId IdType="pubmed">8033378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware JE, Sherbourne CD (1992) The MOS 36-Item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 30(6):473&#x2013;83</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005650-199206000-00002</ArticleId><ArticleId IdType="pubmed">1593914</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferraz LB, Almeida FA, Vasconcellos MR, Faccina AS, Ciconelli RM, Ferraz MB (2006) The impact of lupus erythematosus cutaneous on the Quality of life: the Brazilian-Portuguese version of DLQI. Qual Life Res Int J Qual Life Asp Treat Care Rehabil 15(3):565&#x2013;570</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11136-005-2638-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogunsanya ME, Cho SK, Hudson A, Chong BF (2020) Factors associated with quality of life in cutaneous lupus erythematosus using the Revised Wilson and Cleary Model. Lupus 29(13):1691&#x2013;1703</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320951842</ArticleId><ArticleId IdType="pubmed">32883161</ArticleId><ArticleId IdType="pmc">7641991</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R et al (2019) 2019 European league against rheumatism/american college of rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71(9):1400&#x2013;1412</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId><ArticleId IdType="pmc">6827566</ArticleId></ArticleIdList></Reference><Reference><Citation>Guzm&#xe1;n J, Cardiel MH, Arce-Salinas A, S&#xe1;nchez-Guerrero J, Alarc&#xf3;n-Segovia D (1992) Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 19(10):1551&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pubmed">1464867</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarc&#xf3;n GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677&#x2013;2686</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId><ArticleId IdType="pmc">3409311</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoll T, Seifert B, Isenberg DA (1996) SLICC/ACR damage index is valid, and renal and pulmonary organ scores are predictors of severe outcome in patients with systemic lupus erythematosus. Rheumatology 35(3):248&#x2013;254</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/35.3.248</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht J, Werth VP (2007) Development of the CLASI as an outcome instrument for cutaneous lupus erythematosus. Dermatol Ther 20(2):93&#x2013;101</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1529-8019.2007.00117.x</ArticleId><ArticleId IdType="pubmed">17537137</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S et al (2005) The CLASI (Cutaneous LE Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 125(5):889&#x2013;94</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.0022-202X.2005.23889.x</ArticleId><ArticleId IdType="pubmed">16297185</ArticleId><ArticleId IdType="pmc">3928016</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang AY, Ghazi E, Okawa J, Werth VP (2013) Quality of Life Differences Between Responders and Nonresponders in the Treatment of Cutaneous Lupus Erythematosus. JAMA Dermatol 149(1):104</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/2013.jamadermatol.467</ArticleId><ArticleId IdType="pubmed">23324773</ArticleId><ArticleId IdType="pmc">3928008</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma SM, Okawa J, Propert KJ, Werth VP (2014) The impact of skin damage due to cutaneous lupus on quality of life. Br J Dermatol 170(2):315&#x2013;321</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjd.12653</ArticleId><ArticleId IdType="pubmed">24111880</ArticleId><ArticleId IdType="pmc">4878997</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasquez R, Wang D, Tran QP, Adams-Huet B, Chren MM, Costner MI et al (2013) A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus: Multicentre, cross-sectional quality of life study of patients with CLE. Br J Dermatol 168(1):145&#x2013;153</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2133.2012.11106.x</ArticleId><ArticleId IdType="pubmed">22708924</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal R, Wilke CT, Pickard AS, Vats V, Mikolaitis R, Fogg L et al (2009) Psychometric properties of the euroQol-5D and short form-6D in patients with systemic lupus erythematosus. J Rheumatol 36(6):1209&#x2013;1216</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.081022</ArticleId><ArticleId IdType="pubmed">19369452</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>